Ondansetron/promethazine combination or promethazine alone reduces nausea and vomiting after middle ear surgery

Khalil, Sara; Philbrook, Liza; Rabb, Mary; Wells, Lynda T.; Aves, Teody; Villanueva, Guillermina; Amhan, Muhamad; Chuang, Alice Z.; Lemak, Noreen A.

doi:10.1016/s0952-8180(99)00103-8

Cited by 59 publications

(24 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a dose of 12.5 to 25 mg given towards the end of surgery, it has been shown to be effective for PONV management (IIIB). 70 Its use, however, is limited by sedation and prolonged recovery from anesthesia. 65 A recent study, however, did not show increased awakening time or duration of PACU stay when compared to ondansetron and placebo in patients undergoing middle ear surgery.…”

Section: Other Older Generation Antiemeticsmentioning

confidence: 99%

“…65 A recent study, however, did not show increased awakening time or duration of PACU stay when compared to ondansetron and placebo in patients undergoing middle ear surgery. 70 Similarly, chlorpromazine demonstrated efficacy in the prevention and treatment of PONV (IIIB). 71,72 Its many side effects, particularly sedation and hypotension, limit its use as an antiemetic.…”

Section: Other Older Generation Antiemeticsmentioning

confidence: 99%

See 1 more Smart Citation

Evidence-based management of postoperative nausea and vomiting: a review

Habib

Gan

2004

Can J Anesth/J Can Anesth

196

106

View full text Add to dashboard Cite

P Pu ur rp po os se e: : To provide evidence-based guidelines for the prophylaxis and treatment of postoperative nausea and vomiting (PONV).S So ou ur rc ce e: : Literature from randomized controlled trials, systematic reviews, logistic regression analyses and expert opinion in the management of PONV.P Pr ri in nc ci ip pa al l f fi in nd di in ng gs s: : The etiology of PONV is multifactorial. Patient, anesthesia, and surgery related risk factors have been identified. Universal PONV prophylaxis is not cost-effective. Identification of patients at high-risk of PONV allows targeting prophylaxis to those who will benefit most from it. No prophylaxis is needed for patients at low risk for PONV. For patients at moderate risk for PONV, prophylaxis using a single antiemetic or a combination of two agents should be considered. Double and triple antiemetic combinations should be considered for patients at high risk for PONV. Furthermore, a multimodal approach should be adopted incorporating steps to keep the baseline risk of PONV low. The optimum cost-effective approach to the management of PONV will differ between an ambulatory centre and an inpatient hospital setting. For the treatment of established PONV in patients who failed prophylaxis, patients should not receive a repeat dose of the prophylactic antiemetic. Rather, a drug acting at a different receptor should be used. Beyond six hours after surgery, patients can be treated with any of the agents used for prophylaxis, except dexamethasone and transdermal scopolamine.C Co on nc cl lu us si io on n: : PONV are common after anesthesia and surgery. We provided evidence-based guidelines for the management of this problem based on the available literature. Objectif : Énoncer des lignes de conduite fondées sur des données probantes pour la prévention et le traitement des nausées et des vomissements postopératoires (NVPO). Source : Les publications d'essais contrôlés et randomisés, les études méthodiques, les analyses de régression logistique et l'opinion d'experts sur le traitement des NVPO. Constatations principales : L'origine des NVPO est multifactorielle. Les facteurs de risque reliés au patient, à l'anesthésie et au type de chirurgie sont connus. La prévention universelle des NVPO n'est pas rentable. L'identification des patients à haut risque de NVPO permet

show abstract

Section: Other Older Generation Antiemeticsmentioning

confidence: 99%

Section: Other Older Generation Antiemeticsmentioning

confidence: 99%

Evidence-based management of postoperative nausea and vomiting: a review

Habib

Gan

2004

Can J Anesth/J Can Anesth

196

106

View full text Add to dashboard Cite

show abstract

“…3) Promethazine + another antiemetic vs. placebo or the same antiemetic alone In three clinical trials (19,21,32), combination of promethazine with another antiemetic was compared to placebo or to those same antiemetics administered alone. The study with 87 patients, aged 13 -72 years, reported that a combination of promethazine with ondansetron reduced the incidence of nausea, vomiting and combination of nausea and vomiting when compared with placebo.…”

Section: Fujii (2008) (36)mentioning

confidence: 99%

“…Carlisle (2006) Table 1 evaluating the effectiveness of promethazine: (21), (22), (10), (19), (15), (20), (18) Compared to placebo, the risk for PONV is decreased by promethazine, but there was no evidence that the risk of postoperative vomiting is changed by promethazine.…”

mentioning

confidence: 99%

Promethazine in the treatment of postoperative nausea and vomiting: a systematic review

Markić

Ridge

2011

View full text Add to dashboard Cite

show abstract

“…Promethazine further presents antihistaminic and anticolinergic activity, and is more efficient than ondansetron in PONV prophylaxis in middle ear surgeries. (39) Prochlorperazine has a more rapid action than promethazine and has also sedative effect. Its administration was even more effective in reducing PONV when compared to ondanestron in hip and knee surgeries.…”

Section: Preoperative Strategiesmentioning

confidence: 99%